ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
How does this development compare to similar FDA approvals and clinical progress among ONWD's competitors?
What is the expected timeline and potential market size for the ARC-IM System if the pivotal study is successful?
How will the FDA IDE approval for the Empower BP pivotal study affect ONWD's short-term stock performance?
7 days ago